This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Value Guru Surrounds News Corp., Jumps Into Biotech

BOSTON (TheStreet) -- Seth Klarman, founder of Boston-based hedge fund Baupost Group , made only one big new bet in the fourth quarter: a small biopharmaceutical company called Targacept (TRGT), according to the fund's latest 13F filing.

Klarman is a strict value investor who manages more than $20 billion and prefers to stay out of the media spotlight. Klarman's risk-aversion and his value-investment approach was documented in his 1991 book Margin of Safety: Risk-Averse Value Investing Strategies for the Thoughtful Investor, which was only in publication briefly and is considered the value-investing manual. It now fetches hundreds of dollars on secondary markets.

Seth Klarman, Baupost Group

Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed to the Securities and Exchange Commission within 45 days of the end of a quarter. Funds aren't required to report short positions betting on declines.

Baupost Group held just 22 stocks as of Dec. 31, with oil giant BP (BP) and ViaSat (VSAT) as the two largest holdings based on market value.

BP was a popular pick among value investors after the April 2010 rig explosion in the Gulf of Mexico. BP shares were flat in 2011 but are up 8.7% this year already. Baupost sold 1.7 million shares of BP during the fourth quarter as the stock rallied about 20%.

>>View Seth Klarman's Portfolio

Klarman's newest bet in the fourth quarter was on Targacept, which is up nearly 16% this year. Klarman may have been attracted to the stock after it plunged sharply in early November after Phase III trial results for its TC-5214 depression treatment failed to meet endpoints. Shares of Targacept dropped more than 60% during the quarter. However, Targacept only represents about 1% of Baupost's portfolio.

Klarman didn't initiate any other new positions in the quarter, although he did add to positions in Class B shares of News Corp. (NWS) (which have voting rights), NovaGold Resources (NG), Idenix Pharmaceuticals (IDIX), Aveo Pharmaceuticals (AVEO) and Allied Nevada Gold (ANV).

Klarman sold out of only one position during the quarter: BreitBurn Energy (BBEP), an oil and gas property company whose shares jumped nearly 20% during the fourth quarter. The stock had been in Baupost's portfolio for several years.

In addition to BP, Klarman reduced his stake in a handful of other companies, including tech giant Hewlett-Packard (HPQ), Class A shares of News Corp. (NWS), PDL BioPharma (PDLI), and health care diagnostics company Alere (ALR).

Hewlett-Packard had been one of Klarman's newest bets after he acquired more than 20 million shares of the company during the third quarter. Shares of HP advanced more than 10% during the fourth quarter, which may have prompted Klarman to take some profits. Shares are up another 13% so far in 2012.

-- Written by Robert Holmes in Boston.



>To contact the writer of this article, click here: Robert Holmes.

Readers Also Like:

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs